- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Andrew Ho: After PE Hospitalization, It’s Important to Look Into Logistical Options for Patients
Andrew Ho, MD, talks about the importance of searching for what can be modified, such as closer transition to skilled nursing facilities, when working with patients who had pulmonary embolism (PE) and experienced readmission who had nonmodifiable factors and comorbidities.
Andrew Ho, MD, pulmonary critical care fellow at Temple University Hospital, presented a poster at the CHEST Annual Meeting 2023 where one of the main findings was that pulmonary embolism (PE) readmission rates are impacted by modifiable and nonmodifiable factors.
Transcript
What modifiable factors can be influenced for the better in this population, and what can be implemented to improve these factors for the best patient outcomes?
The main part of the project was looking at the nonmodifiable factors. All the comorbidities that these patients have, these are things that we can't really change. So, going forward, it's like, what can we really do to modify it?
As, we see these patients with higher scores coming back in more often, these are patients who are primed to have closer follow-up, like getting appointments before they leave the hospital, maybe closer transition to skilled nursing facilities or home health care. These are things that can be done for all these patients to ensure they do okay outside and get to all their follow-ups.
Something we hope to see in the future, is there are a lot of advanced therapies coming out for pulmonary embolism. They need to be shown to be safe and effective before use, but if these patients come back in [to the hospital] so often, have higher mortality, and have a lot of cost to the health care system, they might benefit from a more aggressive strategy. But this needs to be shown [with] more research.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
